logo

For the Inventor, By the Inventor

Shanghai, China

Hongyan He

This inventor holds 2 USPTO granted patents and 5 published patent applications. Top assignee: Biomea Fusion, Inc.. Active years: 2024-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongyan He. Retrieved from https://idiyas.com/inventor/hongyan-he-p7w229k2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 12.7

ph-index = 1


Company Filing History:

goldMedal2 out of 12 
 
Biomea Fusion, Inc.
 patents

Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents
1. 12215113 - Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] (2025-02-04),
2. 12018032 - Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction (2024-06-25),

Title: Innovations and Contributions of Inventor Hongyan He

Introduction

Hongyan He is an accomplished inventor based in Shanghai, China, recognized for his significant contributions to the field of pharmaceuticals. With a portfolio of two patents, He exemplifies the driving force of innovation in developing new therapeutic agents aimed at tackling serious medical conditions.

Latest Patents

Hongyan He’s latest patents include groundbreaking work on Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]. This invention describes a compound known as Compound A and its various crystalline forms, solvates, and pharmaceutically acceptable salts. This compound acts as an irreversible inhibitor of the menin-MLL interaction and is pivotal in pharmaceutical compositions that can be employed for treating autoimmune diseases, cancer (including lymphoma), and a range of inflammatory conditions.

Career Highlights

Hongyan He is currently employed at Biomea Fusion, Inc., where he engages in cutting-edge research aimed at expanding the frontiers of drug development. His contributions reflect a deep understanding of medicinal chemistry and pharmacology, positioning him as a key player in his organization.

Collaborations

Throughout his career, He has collaborated with notable professionals in the field, including James T. Palmer and Angelina Sau Man Wong. This teamwork not only enhances his research capabilities but also fosters an environment of innovation through shared expertise and creative problem-solving.

Conclusion

In summary, Hongyan He stands out as a prominent inventor whose latest patents play a fundamental role in advancing pharmaceutical sciences. His work continues to impact the treatment landscape for various diseases, highlighting the importance of innovation in healthcare and the potential for future breakthroughs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…